AROMATASE INHIBITORS MORE EFFECTIVE THAN TAMOXIFEN

摘要

Management of early breast cancer involves aromatase inhibitors (Als) and tamoxifen. To investigate their efficacy, the Early Breast Cancer Trialists' Collaborative Group undertook a meta-analysis of 31,920 postmenopausal women with oestrogen-receptor-positive early breast cancer in nine randomised clinical trials.